Selective Factor XIa Inhibitors for Thrombosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thrombosis, embolism, hypercoagulability, and fibrotic changes are inadequate, as existing Factor XIa inhibitors have limitations in specificity and efficacy, and there is a need for compounds that can effectively inhibit Factor XIa and plasma kallikrein to address these conditions.
Innovation Solution
Development of selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein, represented by compounds of Formula Ia, which are designed to treat or prevent thrombosis, embolism, hypercoagulability, or fibrotic changes by selectively targeting these enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Factor XIa inhibitors are used, then some thrombotic effects are reduced, but specificity and efficacy are insufficient
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure of Factor XIa inhibitors through systematic modification of molecular parameters. The compounds of Formula I feature specific structural parameters (R1-R6 substituents, ring structures, and molecular weight ranges) that are tuned to achieve optimal binding affinity and specificity for Factor XIa while minimizing off-target effects, thereby resolving the contradiction between reliability and harmful effects
Solution Approach 2:
The patent applies local quality by designing inhibitors with specific functional groups and structural features at particular positions within the molecule. The differentiated substituent patterns (e.g., specific R groups at different positions) create localized interactions with the Factor XIa active site that enhance specificity, allowing the inhibitor to distinguish Factor XIa from other serine proteases and thus improve reliability while reducing harmful thrombotic effects
2Object-affected harmful factors
If Factor XIa inhibition is enhanced to improve thrombosis treatment, then thrombotic effects are reduced, but risk of excessive bleeding increases
Solution Approach 1:
The patent employs the intermediary principle by developing Factor XIa inhibitors that act as selective mediators in the coagulation cascade. By specifically targeting Factor XIa without affecting other clotting factors, these inhibitors intermediate between complete coagulation inhibition (which causes bleeding) and insufficient inhibition (which allows thrombosis). The selective mechanism allows thrombotic effects to be reduced while maintaining hemostatic safety
Solution Approach 2:
The patent applies partial action by designing inhibitors that provide moderate, controlled inhibition of Factor XIa rather than complete blockade. The compounds achieve sufficient thromboprophylaxis through partial inhibition of the coagulation cascade, avoiding the excessive action that would lead to hemorrhagic complications. This is accomplished through optimized binding affinity and reversible inhibition mechanisms
Data Source
AI summary
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.